Compare ERNA & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERNA | TNON |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.8M |
| IPO Year | 2021 | 2021 |
| Metric | ERNA | TNON |
|---|---|---|
| Price | $1.97 | $2.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 27.5K | ★ 215.5K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.29 | ★ 84.90 |
| EPS | ★ N/A | N/A |
| Revenue | $582,000.00 | ★ $3,944,000.00 |
| Revenue This Year | N/A | $52.65 |
| Revenue Next Year | N/A | $47.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 20.35 |
| 52 Week Low | $1.84 | $2.10 |
| 52 Week High | $47.25 | $45.50 |
| Indicator | ERNA | TNON |
|---|---|---|
| Relative Strength Index (RSI) | 32.15 | 35.53 |
| Support Level | $1.84 | N/A |
| Resistance Level | $2.26 | $4.18 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 34.08 | 11.11 |
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.